Starr International Co. Inc. bought a new position in Perrigo Company PLC (NYSE:PRGO) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 27,960 shares of the company’s stock, valued at approximately $1,199,000.
Several other institutional investors have also recently added to or reduced their stakes in PRGO. Nisa Investment Advisors LLC lifted its holdings in Perrigo by 8.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 30,641 shares of the company’s stock valued at $1,187,000 after buying an additional 2,400 shares in the last quarter. Atlas Capital Advisors LLC acquired a new stake in Perrigo during the 4th quarter valued at approximately $26,000. Nippon Life Global Investors Americas Inc. lifted its stake in Perrigo by 49.5% during the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 45,850 shares of the company’s stock valued at $1,778,000 after acquiring an additional 15,190 shares during the period. Two Sigma Advisers LP acquired a new stake in Perrigo during the 4th quarter valued at approximately $984,000. Finally, FTB Advisors Inc. lifted its stake in Perrigo by 44.7% during the 1st quarter. FTB Advisors Inc. now owns 65,086 shares of the company’s stock valued at $3,134,000 after acquiring an additional 20,095 shares during the period. Hedge funds and other institutional investors own 83.10% of the company’s stock.
NYSE:PRGO traded down $0.42 during mid-day trading on Friday, hitting $47.35. The stock had a trading volume of 887,204 shares, compared to its average volume of 1,374,256. The stock has a market cap of $6.49 billion, a price-to-earnings ratio of 10.41, a price-to-earnings-growth ratio of 2.62 and a beta of 1.29. Perrigo Company PLC has a twelve month low of $36.28 and a twelve month high of $80.66. The company has a quick ratio of 1.14, a current ratio of 1.64 and a debt-to-equity ratio of 0.48.
Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, May 8th. The company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.13. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Perrigo had a net margin of 2.43% and a return on equity of 10.40%. During the same period in the prior year, the firm posted $1.26 earnings per share. On average, equities analysts anticipate that Perrigo Company PLC will post 3.96 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 18th. Shareholders of record on Friday, May 31st will be paid a $0.21 dividend. This is a positive change from Perrigo’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 1.77%. The ex-dividend date of this dividend is Thursday, May 30th. Perrigo’s dividend payout ratio is currently 16.70%.
A number of research firms have recently issued reports on PRGO. SunTrust Banks dropped their target price on shares of Perrigo to $46.00 and set a “hold” rating for the company in a report on Thursday, April 4th. Royal Bank of Canada set a $48.00 price objective on shares of Perrigo and gave the company a “hold” rating in a report on Thursday, February 28th. ValuEngine lowered shares of Perrigo from a “sell” rating to a “strong sell” rating in a report on Monday, April 1st. Wells Fargo & Co set a $47.00 price objective on shares of Perrigo and gave the company a “hold” rating in a report on Thursday, February 28th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $107.00 price objective on shares of Perrigo in a report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $73.00.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Further Reading: Buy-Side Analysts
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.